Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2017 2
2020 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
The WISDOM study: a new approach to screening can and should be tested.
Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M. Esserman L, et al. Among authors: heditsian d. Breast Cancer Res Treat. 2021 Oct;189(3):593-598. doi: 10.1007/s10549-021-06346-w. Epub 2021 Sep 16. Breast Cancer Res Treat. 2021. PMID: 34529196 No abstract available.
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Parikh DA, Kody L, Brain S, Heditsian D, Lee V, Curtis C, Karin MR, Wapnir IL, Patel MI, Sledge GW Jr, Caswell-Jin JL. Parikh DA, et al. Among authors: heditsian d. Breast Cancer Res Treat. 2022 Jul;194(1):171-178. doi: 10.1007/s10549-022-06611-6. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35538268 Free PMC article.
Advocates' perspective: neoadjuvant chemotherapy for breast cancer.
Perlmutter J, Axler S, Baas C, Beckwith BJ, Bonoff A, Brain S, Delapine M, Devine M, Frank E, Fraser V, Gallece M, Geoghegan C, Hamade H, Heditsian D, Hirschhorn B, Kandell S, Laxague D, Lestage B, Lyzen M, Madden D, Mertz SA, Parker BJ, Roach N, Sauers N, Vincent L, Waddell D, Wetzel M, Wright K. Perlmutter J, et al. Among authors: heditsian d. J Clin Oncol. 2012 Dec 20;30(36):4586-8; author reply 4588-9. doi: 10.1200/JCO.2012.44.1824. Epub 2012 Nov 19. J Clin Oncol. 2012. PMID: 23169512 No abstract available.
Rationale, Study Design, and Cohort Characteristics for the Markers for Environmental Exposures (MEE) Study.
Lucia RM, Huang WL, Alvarez A, Thampy D, Elyasian M, Hidajat A, Yang K, Forman D, Pebdani A, Masunaka I, Brain S, Heditsian D, Lee V, Goodman D, Norden-Krichmar TM, Odegaard AO, Ziogas A, Park HL. Lucia RM, et al. Among authors: heditsian d. Int J Environ Res Public Health. 2020 Mar 9;17(5):1774. doi: 10.3390/ijerph17051774. Int J Environ Res Public Health. 2020. PMID: 32182891 Free PMC article.
18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM. Diwanji D, et al. Among authors: heditsian d. Radiol Imaging Cancer. 2024 Mar;6(2):e230082. doi: 10.1148/rycan.230082. Radiol Imaging Cancer. 2024. PMID: 38551406 Free PMC article.
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Bartelink IH, et al. Among authors: heditsian d. Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4. Breast Cancer Res. 2017. PMID: 28893315 Free PMC article.